Paradigm Shift in Management of Hyperglycemia in Patients with Type 2 Diabetes: Glucocentric versus Organ Protection (original) (raw)

1.Powers AC, Fowler MJ, Rickels MRDiabetes mellitus: management and therapies. In: Loscalzo J, Fauci A, Kasper D, Hauser S, Longo D, Jameson JL, eds. Harrison's principles of internal medicine. 21st ed.New York, NY: McGraw Hill; 2022.

2.Di Angelantonio E, Gao P, Khan H, Butterworth AS, Wormser D, Kaptoge S, et al. Glycated hemoglobin mea-surement and prediction of cardiovascular disease. JAMA 2014;311:1225-33.

3.UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998 352:837-53. Erratum in: Lancet 1999;354: 602.

4.Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12.

5.Pirart J. Diabetes mellitus and its degenerative complications: a prospective study of 4,400 patients observed between 1947 and 1973. Diabetes Care 1978;1:252-63.

6.World Health Organization (WHO)Use of glycated hae-moglobin (HbA1c) in diagnosis of diabetes mellitus: ab-breviated report of a WHO consultation. Geneva: WHO; 2011.

7.Marx N, McGuire DK, Perkovic V, Woerle HJ, Broedl UC, von Eynatten M, et al. Composite primary end points in cardiovascular outcomes trials involving type 2 diabetes patients: should unstable angina be included in the primary end point? Diabetes Care 2017;40:1144-51.

8.Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89.

9.Stratton IM, Cull CA, Adler AI, Matthews DR, Neil HA, Holman RR. Additive effects of glycaemia and blood pres-sure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75). Diabeto-logia 2006;49:1761-9.

10.Haffner SM. The Scandinavian Simvastatin Survival Study (4S) subgroup analysis of diabetic subjects: implications for the prevention of coronary heart disease. Diabetes Care 1997;20:469-71.

11.Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008;358:580-91.

12.Ko SH, Kim SR, Kim DJ, Oh SJ, Lee HJ, Shim KH, et al. 2011 Clinical practice guidelines for type 2 diabetes in Korea. Diabetes Metab J 2011 35:431-6. Erratum in: Diabetes Metab J 2011;35: 642.

13.Gerstein HC, Miller ME, Ismail-Beigi F, Largay J, Mc-Donald C, Lochnan HA, et al; ACCORD Study Group. Effects of intensive glycaemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial. Lancet 2014;384:1936-41.

14.Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72.

15.Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-39.

16.Currie CJ, Peters JR, Tynan A, Evans M, Heine RJ, Bracco OL, et al. Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study. Lancet 2010;375:481-9.

17.Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Fer-rannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38:140-9.

18.U. S. Food and Drug AdministrationGuidance for indus-try on diabetes mellitus-evaluating cardiovascular risk in new anti-diabetic therapies to treat type 2 diabetes. Silver Spring, MD: U. S. Food and Drug Administration; 2008.

19.Bae JH, Han KD, Ko SH, Yang YS, Choi JH, Choi KM, et al. Diabetes fact sheet in Korea 2021. Diabetes Metab J 2022;46:417-26.

20.Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al; SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317-26.

21.Scheen AJ. Cardiovascular effects of new oral glucose-low-ering agents: DPP-4 and SGLT-2 inhibitors. Circ Res 2018;122:1439-59.

22.Sano M. Mechanism by which dipeptidyl peptidase-4 inhibitors increase the risk of heart failure and possible differences in heart failure risk. J Cardiol 2019;73:28-32.

23.Ko SH, Hur KY, Rhee SY, Kim NH, Moon MK, Park SO, et al; Committee of Clinical Practice Guideline of Korean Diabetes Association. Antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus 2017: a position statement of the Korean Diabetes Association. Diabetes Metab J 2017;41:337-48.

24.Kim GS, Park JH, Won JC. The role of glucagon-like pep-tide 1 receptor agonists and sodium-glucose cotransporter 2 inhibitors in reducing cardiovascular events in patients with type 2 diabetes. Endocrinol Metab (Seoul) 2019;34:106-16.

25.Vaduganathan M, Januzzi JL Jr. Preventing and treating heart failure with sodium-glucose co-transporter 2 inhibitors. Am J Med 2019;132(10 Suppl):S21-9.

26.Home P. Controversies for glucose control targets in type 2 diabetes: exposing the common ground. Diabetes Care 2019;42:1615-23.

27.Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al; DAPA-CKD Trial Com-mittees and Investigators. Dapagliflozin in patients with chronic kidney disease. N Engl J Med 2020;383:1436-46.

28.Ryan DH, Lingvay I, Colhoun HM, Deanfield J, Emerson SS, Kahn SE, et al. Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT) rationale and design. Am Heart J 2020;229:61-9.

29.Hur KY, Moon MK, Park JS, Kim SK, Lee SH, Yun JS, et al. 2021 Clinical practice guidelines for diabetes mellitus of the Korean Diabetes Association. Diabetes Metab J 2021;45:461-81.

30.Kibble JD, Halsey CRMedical physiology: the big picture. New York, NY: McGraw Hill; 2014. Notice.

31.Banting FG, Best CH, Collip JB, Campbell WR, Fletcher AA. Pancreatic extracts in the treatment of diabetes mellitus. Can Med Assoc J 1922;12:141-6.